Spinal Muscular Atrophy Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Veröffentlicht von: precision business insights
Veröffentlicht am: 28.03.2018 07:36
Rubrik: Gesundheit & Medizin


(Presseportal openBroadcast) - Spinal Muscular Atrophy Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Pressekontakt:

Spinal Muscular Atrophy Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Spinal Muscular Atrophy Disease Pipeline Drugs Assessment

Overview:
Spinal Muscular Atrophy is a genetic neuromuscular disease which is characterized by muscle atrophy and weakness. This disease generally manifests in early ages and may leads to the genetic cause of death in toddlers and infants. SMA is caused due to the defects in Survival Motor Neuron 1 (SMN1) gene which encodes the SMN protein. The SMN protein plays a vital role in health and survival of nerve cells in spinal cord responsible for muscle contraction (motor neurons).
Symptoms of SMA includes weak arms and legs, movement problems, tremors, swallowing problems, difficulty in breathing, problems in joints and bones.Spinal Muscular Atrophy is diagnosed by molecular genetic testing, electromyogram, CT Scan, MRI, Muscle tissue biopsy. Spirinza (Nusinersen) is the only FDA approved drug to treat SMA. Spirinza was approved in 2016 by U.S. FDA.


A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/spinal-muscular-atrophy-disease-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx

Segmentation:
By Trial Phase, Spinal Muscular Atrophy pipeline drugs are segmented as:
• Preclinical Trials
• Phase 1
• Phase 2
• Phase 3
• Phase 4
By Company, Spinal Muscular Atrophy pipeline drugs are segmented as:
• Novartis
• Ionis Pharmaceuticals
• Biogen
• Hoffmann-La Roche Ltd
• PTC Therapeutics
• Cytokinetics
• Sanofi
• Genzyme
• Others
By Drugs, Spinal Muscular Atrophy pipeline drugs are segmented as:
• Hydroxyurea
• Branaplam
• Pyridostigmine Bromide
• Nusinersen
• Valproic Acid
• Levocarnitine
• Celecoxib
• Sodium phenylbutyrate
• Others
By Mechanism of Action, Spinal Muscular Atrophy pipeline drugs are segmented as:
• survival of motor neuron SMN2 Splicing Modifier
• Neuroprotectant
• SMN Gene Replacement
• Muscle Activator
• Others
By Types of Spinal Muscular Atrophy diseases, Spinal Muscular Atrophy pipeline drugs are segmented as:
• SMA Type 0
• SMA Type 1
• SMA Type 2
• SMA Type 3
• SMA Type 4
By Route of Administration, Spinal Muscular Atrophy pipeline drugs are segmented as:
• Oral
• Parenteral

To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/spinal-muscular-atrophy-disease-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu


Space Analysis:
• In November 2017, Catalyst Pharmaceuticals, Inc initiated phase II proof-of concept study determining the safety, efficacy and tolerability of its pipeline molecule, Firdapse (amifampridine phosphate) for the treatment of spinal muscular atrophy type 3.
• In December 2017, AveXis, Inc, initiated Phase I clinical trial of AVXS-101 for patients with spinal muscular atrophy type 2 via intrathecal route. AVXS-101 is a proprietary gene therapy candidate of a one-time treatment for SMA Types 1 and 2, designed to address the monogenic root cause of SMA and prevent further muscle degeneration by addressing the defective and/or loss of the primary SMN gene. AVXS-101 also targets motor neurons, providing rapid onset of effect and crossing the blood brain barrier to allow targeting of both central and systemic features.

Report Description:
Spinal Muscular Atrophy Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Spinal Muscular Atrophy treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Spinal Muscular Atrophy disease pipeline drugs development. This report studies the dynamics of the Spinal Muscular Atrophy Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Spinal Muscular Atrophy disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/spinal-muscular-atrophy-disease-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3


Key Features of the Report:
• Provides the information related to universities and research institutes working in the therapeutics development
• Report comprehensively covers the all active and discontinued studies
• Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
• Presents the prominent targets for drug development in each stage of clinical trial
• Provides the in-depth analysis on the each drug candidates in the clinical trial phases
Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/spinal-muscular-atrophy-disease-pipeline-drugs-assessment/
About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,
152 – 160 City Road,
London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com



Bitte beachten Sie, dass für den Inhalt der hier veröffentlichten Meldung nicht openBroadcast verantwortlich ist, sondern der Verfasser der jeweiligen Meldung selbst. AGB | Haftungsausschluss.